Aerosol Delivery of Lung Surfactant and Nasal CPAP in the Treatment of Neonatal Respiratory Distress Syndrome
Year: 2022
Type: review
Abstract: After shifting away from invasive mechanical ventilation and intratracheal instillation of surfactant toward non-invasive ventilation with nasal CPAP and less invasive surfactant administration in order to prevent bronchopulmonary dysplasia in preterm infants with respiratory distress syndrome, fully non-invasive surfactant nebulization is the next Holy Grail in neonatology. Here we review the characteristics of animal-derived (clinical) and new advanced synthetic lung surfactants and improvements in nebulization technology required to secure optimal lung deposition and effectivity of non-invasive lung surfactant administration. Studies in surfactant-deficient animals and preterm infants have demonstrated the safety and potential of non-invasive surfactant administration, but also provide new directions for the development of synthetic lung surfactant destined for aerosol delivery, implementation of breath-actuated nebulization and optimization of nasal CPAP, nebulizer circuit and nasal interface. Surfactant nebulization may offer a truly non-invasive option for surfactant delivery to preterm infants in the near future.
Source: Frontiers in Pediatrics
Authors: Frans J. Walther, Alan J. Waring
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,994
Awards: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center - to develop synthetic aerosolized lung surfactant and non-invasive delivery device for use in respiratory distress syndrome (RDS) a significant caus..., Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center - to expedite the necessary preclinical testing of multiple candidate drug formulations to determine the best drug formulation to use in future human...
OpenAlex ID: W4282980281